From the Journals

Testing Metformin’s Reach in PAD

Double-blind trial of 202 patients shows no improvement in 6-minute walk distance at 6 months compared with placebo.

Share

7 Key Takeaways

  • 1

    PERMET trial studied metformin's effect on adults with PAD without diabetes.

  • 2

    202 participants were enrolled across 4 US sites from May 2017 to February 202

  • 3

    No significant improvement in walking distance observed at 6 months.

  • 4

    Common adverse events included indigestion/stomach upset.

  • 5

    89% of participants completed the trial.

  • 6

    Results contradicted earlier studies suggesting metformin benefits.

  • 7

    Trial funded by National Heart, Lung, and Blood Institute.

Original Source(s)

Testing Metformin’s Reach in PAD

Double-blind trial of 202 patients shows no improvement in 6-minute walk distance at 6 months compared with placebo.

  • by Kerri Miller

  • November 11, 2025

  • 4 min

Related Content

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

FDA Approves First Once-Daily Oral Therapy for Acromegaly

Once-daily paltusotine offers an oral alternative to monthly injections for eligible adults.

Diabetes Affects 1 in 6 US Adults: CDC Data

In a stark reflection of diabetes screening gaps, more than one-quarter of U.S. adults with diabetes remained undiagnosed in 2021-2023, with obesity linked to a nearly four-fold higher prevalence compared to normal-weight individuals.